Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | TGM2 | P21980 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.38 |
| ▸ | FKBP4 | Q02790 | 2/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.37 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29948271 | 0.93 | KMT2A (0.55) | KMT2AATMCA2TGM2F2 | |
| SCHEMBL23630459 | 0.93 | KMT2A (0.55) | KMT2AATMCA2TGM2F2 | |
| SCHEMBL30225379 | 0.85 | KMT2A (0.44) | KMT2AATMTGM2F2PRSS1 | |
| SCHEMBL8366178 | 0.80 | KMT2A (0.55) | KMT2AATMCA2TGM2F2 | |
| SCHEMBL23630601 | 0.74 | CCR4 (0.40) | — | |
| SCHEMBL4126919 | 0.74 | KMT2A (0.51) | KMT2AATMCA2TGM2F2 | |
| SCHEMBL29948257 | 0.74 | CCR4 (0.40) | — | |
| SCHEMBL23630364 | 0.74 | CASP3 (0.43) | — | |
| SCHEMBL29948321 | 0.74 | CASP3 (0.43) | — | |
| SCHEMBL16669181 | 0.73 | KMT2A (0.50) | KMT2AATMCA2TGM2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230039836-A1 | AROMATIC SULPHONAMIDES DERIVATIVES THAT INHIBITS PDI A3, THEIR SYNTHESIS AND USE | UNIWERSYTET JAGIELLONSKI (PL) | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039836-A1 | AROMATIC SULPHONAMIDES DERIVATIVES THAT INHIBITS PDI A3, THEIR SYNTHESIS AND USE | PDIA3, PDIA5, PDIA6 | KMT2A 4490/4885ATM 3114/4885CA2 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.